IL-27 upregulates TLRs in cancer cells and immune cells, resulting in enhanced cellular responsiveness to TLR agonists, supporting the combination of IL-27 and TLR agonists as a potential cancer therapy (39–42, 76–79). Here, IL27 is linked to cancer.